The authors present in this part the creation of first radioactiv drugs, since the discovery of radium to the first World War. They present the industrial and chemist Emile Armet de Lisle and the pharmacist Alexandre Antonin Jaboin, first manufacturers of those new way of treatment.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Real-world safety and effectiveness of radium-223 in patients with metastatic castration-resistant prostate cancer: Interim analyses of the prospective, observational RAPIT study.
Int J Cancer
October 2024
Graduate Institute of Clinical Medical Science, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Several life-prolonging therapies for metastatic castration-resistant prostate cancer (mCRPC) are available, including radium-223 dichloride (Ra), which was approved based on phase 3 data demonstrating improved overall survival (OS) and a favorable safety profile. To date, real-world evidence for Ra use in Taiwan is from three studies of <50 patients. This observational study (NCT04232761) enrolled male patients with histologically/cytologically confirmed mCRPC with bone metastases from centers across Taiwan.
View Article and Find Full Text PDFEuropean Society of Gynaecological Oncology expanded quality indicators and accreditation for cervical cancer management.
Int J Gynecol Cancer
April 2024
Hôpital Universitaire Pitié Salpêtrière, Paris, Île-de-France, France.
Micellar solution of [Ra]RaCl: Reaching renal excretion, potent efficacy in osteoblastic osteosarcoma in PDX model, biochemistry alterations and pharmacokinetics.
Int J Pharm
March 2024
Brazilian Nuclear Energy Commission, Nuclear Engineering Institute, Laboratory of Nanoradiopharmaceuticals and Synthesis of Novel Radiopharmaceuticals, Rio de Janeiro 21941906, Brazil; State University of Rio de Janeiro, Laboratory of Radiopharmacy and Nanoradiopharmaceuticals, Rio de Janeiro 23070200, Brazil. Electronic address:
Despite the successful use of the radiopharmaceutical radium-223 dichloride ([Ra]RaCl) for targeted alpha therapy of castration-resistant prostate cancer patients with bone metastases, some short-term side effects, such as diarrhea and vomiting, have been documented, causing patient discomfort. Hence, we prepared a nanosized micellar solution of [Ra]RaCl and evaluated its biodistribution, pharmacokinetics, and induced biochemical changes in healthy mice up to 96 h after intraperitoneal administration as an alternative to overcome the previous limitations. In addition, we evaluated the bone specificity of micellar [Ra]RaCl in patient-derived xenografts in the osteosarcoma model.
View Article and Find Full Text PDFThe DASciS Software for BSI Calculation as a Valuable Prognostic Tool in mCRPC Treated with 223RaCl2: A Multicenter Italian Study.
Biomedicines
April 2023
Department of Radiological Sciences, Oncology and Anatomo-Pathology, Sapienza, University of Rome, 00161 Rome, Italy.
Background/aim: Radium-223 dichloride (RaCl) represents a therapeutic option for metastatic castration-resistant prostate cancer (mCRPC) patients dealing with symptomatic bone metastases. The identification of baseline variables potentially affecting the life-prolonging role of RaCl is still ongoing. Bone scan index (BSI) defines the total load of bone metastatic disease detected on a bone scan (BS) and is expressed as a percentage value of the whole bone mass.
View Article and Find Full Text PDFAuthor Correction: Early response evaluation by single cell signaling profiling in acute myeloid leukemia.
Nat Commun
March 2023
Centre for Cancer Biomarkers (CCBIO), Department of Clinical Science, University of Bergen, Bergen, Norway.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!